CERT icon

Certara

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 73.3%
Negative

Positive
Seeking Alpha
13 hours ago
Why Investors Should Consider Certara Again
Certara posted strong Q1 and Q2 results, with revenue growth and non-GAAP EPS exceeding expectations, driven by biosimulation software and services. Certara's AI-enabled platforms, including the upcoming AI MIDD and CertaraIQ, are positioned as catalysts for sustainable, long-term growth in drug development. Despite a large total addressable market and cost control, Certara faces analyst downgrades, subdued market conditions, and high short interest.
Why Investors Should Consider Certara Again
Neutral
GlobeNewsWire
5 days ago
Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025
RADNOR, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2025 after the market close on Thursday, November 6th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET.
Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025
Neutral
CNBC Television
22 days ago
Final Trade: CERT, GDX, IWM, MPC
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Final Trade: CERT, GDX, IWM, MPC
Neutral
Seeking Alpha
1 month ago
Certara, Inc. (CERT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Certara, Inc. (NASDAQ:CERT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 12:20 PM EDT Company Participants John Gallagher - SVP, Principal Accounting Officer & Chief Financial Officer Conference Call Participants Craig Hettenbach - Morgan Stanley, Research Division Presentation Craig Hettenbach VP & Equity Analyst All right. I think we're on time here.
Certara, Inc. (CERT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral
Seeking Alpha
1 month ago
Certara, Inc. (CERT) Presents At Baird Global Healthcare Conference 2025 (Transcript)
Certara, Inc. (NASDAQ:CERT ) Baird Global Healthcare Conference 2025 September 9, 2025 10:15 AM EDT Company Participants William Feehery - CEO & Director John Gallagher - SVP, Principal Accounting Officer & Chief Financial Officer Conference Call Participants Joseph Vruwink - Robert W. Baird & Co. Incorporated, Research Division Presentation Joseph Vruwink Senior Research Analyst All right.
Certara, Inc. (CERT) Presents At Baird Global Healthcare Conference 2025 (Transcript)
Neutral
GlobeNewsWire
1 month ago
Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster
RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the availability of Pinnacle 21 Enterprise Plus.
Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster
Neutral
GlobeNewsWire
1 month ago
Certara to Participate in Upcoming Investor Conferences
RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:
Certara to Participate in Upcoming Investor Conferences
Neutral
Seeking Alpha
1 month ago
Cerrado Gold Inc. (CRDOF) Q2 2025 Earnings Call Transcript
Cerrado Gold Inc. (OTCQX:CRDOF) Q2 2025 Earnings Conference Call August 25, 2025 11:00 AM ET Company Participants Michael McAllister - Vice President of Investor Relations Mark Peter Brennan - CEO & Chairman Jason Brooks - Chief Financial Officer Conference Call Participants Operator Thank you for standing by. This is the conference operator.
Cerrado Gold Inc. (CRDOF) Q2 2025 Earnings Call Transcript
Neutral
Seeking Alpha
2 months ago
Certara, Inc. (CERT) Q2 2025 Earnings Call Transcript
Certara, Inc. (NASDAQ:CERT ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants John E. Gallagher - SVP, Principal Accounting Officer & Chief Financial Officer William F.
Certara, Inc. (CERT) Q2 2025 Earnings Call Transcript
Positive
The Motley Fool
2 months ago
Certara (CERT) Q2 Revenue Jumps 12%
Certara (CERT -3.35%), a leader in biosimulation software and Model-Informed Drug Development solutions, released its Q2 FY2025 earnings on August 6, 2025. The most notable news was a slight revenue beat, with reported GAAP revenue of $104.6 million, exceeding analyst expectations, but non-GAAP earnings per share (EPS) missed consensus by $0.03.
Certara (CERT) Q2 Revenue Jumps 12%